EpiPen shortage shows company, regulator failure, FT says

The worldwide shortage of EpiPens shows a failure by Mylan (MYL), the company that owns the rights to the auto-injectors, and the regulators to monitor them, the Financial Times says, in an opinion piece by Michael Skapinker. Mylan did not pay enough to sub-contractor Pfizer’s (PFE) performance and unnecessarily early expiration dates on the EpiPens increased sales but contributed to the shortage, according to Skapinker.
https://thefly.com/landingPageNews.php?id=2798217